On Monday, Citi reiterated a Impartial score on 23andMe Holding Co (NASDAQ: ME ) inventory, with a value goal of $0.42. The corporate’s feedback come after 23andMe offered further trial information on the European Society for Medical Oncology (ESMO) Congress.
These information embrace outcomes from a Section 1/2a trial of the anti-CD200R1 antibody 23ME-00610, and nonclinical outcomes from the anti-ULBP6 antibody 23ME-01473.
Within the 23ME-00610 trial, partial responses have been noticed in a transparent cell renal cell carcinoma (ccRCC) cohort of 10 sufferers. This response confirmed a 38% discount in measured tumor burden.
Moreover, the corporate offered information on 13 sufferers with domestically superior or metastatic tumor burden-high (TMB-Excessive; n=11) and/or tumor microsatellite instability-high (MSI; n=5). Outcomes confirmed acceptable tolerability and intact peripheral goal engagement, however restricted antitumor exercise when used as monotherapy.
Citi analysts famous that whereas the info are fascinating, they’re nonetheless preliminary and the pattern dimension is small. The corporate mentioned buyers’ focus could stay on potential updates on Anne Wojcicki’s acquisition of 23andMe. Buyers are additionally looking out for any different gives after Wojcicki’s current assertion that he was prepared to think about third-party takeover proposals.
The continued give attention to 23andMe’s company improvement, together with acquisition negotiations, is a vital focus for shareholders and potential buyers. Because the scenario develops, the funding neighborhood is extremely anticipating the most recent developments in these company dynamics.
In different current information, 23andMe Holding Co. reported a 34% decline in first-quarter 2025 income to $40 million, primarily because of the termination of its partnership with GlaxoSmithKline (GSK). Nevertheless, the corporate’s internet loss improved throughout the quarter, rising to $69 million from $105 million a yr earlier.
Lemonaid Well being, a subsidiary of 23andMe, has launched a brand new weight reduction program that features entry to GLP-1 medication akin to Ozempic®, Wegovy® and semaglutide complicated by way of a month-to-month subscription mannequin.
Moreover, 23andMe shareholders permitted a reverse inventory break up to mix excellent shares of Class A and Class B widespread inventory in a ratio decided by the Board of Administrators. In keeping with stories within the current 8-Ok submitting, Anne Wojcicki and Peter Taylor have been re-elected to the corporate’s board of administrators.
The corporate can also be actively growing synthetic intelligence fashions and launching large-scale genetic analysis, demonstrating its dedication to bettering its remedy and analysis capabilities. These are the most recent developments that buyers ought to pay attention to.
This text was generated with the assist of synthetic intelligence and reviewed by an editor. For extra data, please see our phrases and situations.
